# Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation

Study · id `cardio:ct-nct05450328` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05450328](<https://clinicaltrials.gov/study/NCT05450328>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05450328

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 141 participants.

## Technical summary

Registry record NCT05450328. Randomized; triple masking; primary purpose treatment. Start 2025-12-10 (actual); primary completion 2028-05-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 141 participants (planned count; ClinicalTrials.gov record NCT05450328, source copy `cardio:ctgov-nct05450328-2026-06-25`, retrieved 2026-10-26)
- Started: 2025-12-10 (actual) (ClinicalTrials.gov record NCT05450328, source copy `cardio:ctgov-nct05450328-2026-06-25`, retrieved 2026-10-26)
- Primary completion: 2028-05-01 (anticipated) (ClinicalTrials.gov record NCT05450328, source copy `cardio:ctgov-nct05450328-2026-06-25`, retrieved 2026-10-26)
- Completion: 2028-12-01 (anticipated) (ClinicalTrials.gov record NCT05450328, source copy `cardio:ctgov-nct05450328-2026-06-25`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT05450328, source copy `cardio:ctgov-nct05450328-2026-06-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05450328-2026-06-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation
- Acronym: MILAN
- Condition: Right Heart Failure
- Condition: Right Ventricular Dysfunction
- Intervention (Drug): Combined Epoprostenol Sodium & Milrinone
- Intervention (Drug): Normal saline
- Lead sponsor: Montreal Heart Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Montreal Heart Institute (`cardio:org-montreal-heart-institute`)

## Provenance

Content hash: d47499d1fbb5cce307090b115ca2cef5729e3aa6af0e160e38f0efc9694bb5f2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
